Venrock

Averto Medical specializes in the manufacture of medical devices designed to improve outcomes for patients with gastrointestinal diseases. Their innovative solutions aim to facilitate minimally invasive colorectal tumor removal and other gastrointestinal surgeries, enabling healthcare professionals to provide optimal care.

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Accompany Health provides comprehensive in-home primary care, including chronic illness management and treatment of new symptoms, and coordinates care across the full patient journey. The company offers at-home and virtual care, with round-the-clock support to address health needs any time, day or night. It focuses on cultivating long-term relationships with patients, ensuring consistent access to care and a stable point of contact year after year. Accompany Health serves individuals with complex needs, including low-income populations, helping them manage health journeys effectively and improve outcomes. By combining clinical delivery with technology-enabled care coordination, the company aims to reduce barriers such as waiting rooms and lines and to provide dignified care that supports patients throughout ongoing management of chronic conditions and new symptoms.

Tisento Therapeutics, based in Massachusetts, specializes in developing innovative medicines to address diseases with substantial unmet medical needs. Its primary focus is on Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke (MELAS), a severe mitochondrial disorder. The company's therapies aim to treat mitochondrial diseases, both in the central nervous system and peripherally, by targeting key aspects of the disease's pathophysiology, including neuronal and mitochondrial function, cerebrovascular hemodynamics, and inflammatory processes. This approach enables patients to receive treatment promptly.

Pharvaris is a clinical-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE). Its lead drug candidate, PHA121, is currently in Phase 1 clinical trials.

Lyra Therapeutics is a clinical-stage therapeutics company focused on the development and commercialization of localized treatments for ear, nose, and throat diseases. Its XTreo platform is designed to deliver medicines directly to affected tissue for sustained effect with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices intended for in-office administration to provide up to six months of continuous therapy to the sinonasal passages for chronic rhinosinusitis, with mometasone furoate as the active ingredient. Founded in 2005 and headquartered in Watertown, Massachusetts.

The Public Health Company is a pioneering firm that specializes in biosecurity solutions, offering a SaaS-enabled platform designed for the management of bio-risks. Founded in 2020 and headquartered in Palo Alto, California, the company leverages advanced technology and expert knowledge to address the challenges of enterprise risk management. Its platform focuses on identifying and mitigating physical world threats across various applications, providing clients with actionable and predictive intelligence. This enables organizations to implement dynamic risk management strategies efficiently and effectively, enhancing their preparedness against potential biohazards.

Lyra Therapeutics is a clinical-stage therapeutics company focused on the development and commercialization of localized treatments for ear, nose, and throat diseases. Its XTreo platform is designed to deliver medicines directly to affected tissue for sustained effect with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices intended for in-office administration to provide up to six months of continuous therapy to the sinonasal passages for chronic rhinosinusitis, with mometasone furoate as the active ingredient. Founded in 2005 and headquartered in Watertown, Massachusetts.

Stride Health, Inc. is a health benefits platform that specializes in providing affordable health coverage options for independent workers and part-time employees in the United States. The company offers a range of services, including dental plans, doctor and prescription insurance plans, and various health coverage options tailored to meet the needs of its customers. Stride Health simplifies the enrollment process by guiding users through selecting the most cost-effective health plans, aiming to optimize their tax benefits and enhance their take-home pay. Founded in 2013 and based in San Francisco, California, the company was previously known as Covered, Inc. and rebranded to Stride Health, Inc. in March 2013. Stride Health also provides personal advisory services to assist clients in navigating the complexities of their health insurance options.

Aadi Bioscience is a clinical-stage biopharmaceutical company developing precision therapies for cancers driven by mTOR pathway alterations. It focuses on targeted mTOR inhibitors to treat genetically defined cancers, including alterations in TSC1 or TSC2 genes, where conventional inhibitors have struggled with pharmacology, delivery, safety, or tumor targeting. The company is advancing ABI-009, a clinical-phase mTOR inhibitor intended for oncology indications as well as cardiovascular and metabolic contexts. Aadi aims to bring transformative therapies to patients with ultra-rare cancers such as PEComa, and it traces its origins to an earlier name, with its operations based in Pacific Palisades, California, and a founding year of 2011.

The Public Health Company is a pioneering firm that specializes in biosecurity solutions, offering a SaaS-enabled platform designed for the management of bio-risks. Founded in 2020 and headquartered in Palo Alto, California, the company leverages advanced technology and expert knowledge to address the challenges of enterprise risk management. Its platform focuses on identifying and mitigating physical world threats across various applications, providing clients with actionable and predictive intelligence. This enables organizations to implement dynamic risk management strategies efficiently and effectively, enhancing their preparedness against potential biohazards.

Pharvaris is a clinical-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE). Its lead drug candidate, PHA121, is currently in Phase 1 clinical trials.

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Founded in 2017, Devoted Health is dedicated to enhancing the health and well-being of older Americans by offering integrated Medicare Advantage plans. They provide personalized care through a combination of local providers, virtual and in-home care, dedicated guides, and advanced technology.

Lyra Health operates a digital health platform that enhances mental health care for employees by connecting them with a curated network of therapists and coaches. Founded in 2015 and based in Burlingame, California, Lyra uses matching technology to pair individuals with suitable providers based on their needs and preferences. The platform offers live video therapy, coaching, and digital self-care tools, ensuring faster access to care and better outcomes compared to traditional plans. Lyra assesses treatment effectiveness using clinical measures like the PHQ-9 and GAD-7 for conditions such as anxiety and depression. This approach results in significantly more people receiving care and achieving improved mental health outcomes.

Virta Health is a San Francisco–based health technology company that specializes in treating type 2 diabetes through an online, physician-supported program. The company combines nutritional biochemistry, data science, and digital tools to deliver on-demand care via a continuous remote care platform, providing physicians and health coaches who guide patients to reduce blood sugar and lose weight without medications or surgery. Founded in 2014, Virta offers a treatment approach aimed at reversing type 2 diabetes and improving related metabolic and cardiovascular health.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Pharvaris is a clinical-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE). Its lead drug candidate, PHA121, is currently in Phase 1 clinical trials.

Biolux Research Ltd. is a developer of innovative orthodontic technologies and products, primarily focused on reducing treatment timelines and enhancing patient comfort. The company offers OrthoPulse, an infra-red dental stimulation device that utilizes low levels of light energy to stimulate the bone around tooth roots, facilitating tooth movement and potentially decreasing the duration of orthodontic treatments. Additionally, Biolux Research provides OsseoPulse, a bone regeneration system aimed at improving dental outcomes. Founded in 2003 and headquartered in Vancouver, Canada, Biolux Research emphasizes making dental procedures less invasive and more efficient, leveraging advanced techniques such as photobiomodulation and photodynamic therapy to support complex dental cases.

Sojournix Inc., established in 2016 and headquartered in Waltham, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for women's health and neuroendocrine disorders. Its primary focus is SJX-653, a selective neurokinin-3 (NK3) antagonist, designed as a non-hormonal treatment option for moderate to severe vasomotor symptoms associated with menopause.

Founded in 2017, Devoted Health is dedicated to enhancing the health and well-being of older Americans by offering integrated Medicare Advantage plans. They provide personalized care through a combination of local providers, virtual and in-home care, dedicated guides, and advanced technology.

Orchard Therapeutics is a UK-based biopharmaceutical company dedicated to developing and commercializing innovative gene therapies for rare diseases. Its core focus is autologous ex vivo gene therapy, transforming hematopoietic stem cells into a gene-modified drug product for single-administration treatments. The company's portfolio includes Strimvelis, approved by the EMA in 2016, and several programs in advanced registrational studies across various disease areas.

Lyra Health operates a digital health platform that enhances mental health care for employees by connecting them with a curated network of therapists and coaches. Founded in 2015 and based in Burlingame, California, Lyra uses matching technology to pair individuals with suitable providers based on their needs and preferences. The platform offers live video therapy, coaching, and digital self-care tools, ensuring faster access to care and better outcomes compared to traditional plans. Lyra assesses treatment effectiveness using clinical measures like the PHQ-9 and GAD-7 for conditions such as anxiety and depression. This approach results in significantly more people receiving care and achieving improved mental health outcomes.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Virta Health is a San Francisco–based health technology company that specializes in treating type 2 diabetes through an online, physician-supported program. The company combines nutritional biochemistry, data science, and digital tools to deliver on-demand care via a continuous remote care platform, providing physicians and health coaches who guide patients to reduce blood sugar and lose weight without medications or surgery. Founded in 2014, Virta offers a treatment approach aimed at reversing type 2 diabetes and improving related metabolic and cardiovascular health.

Unity Biotechnology is a biotechnology company dedicated to developing therapeutics that prevent, halt, or reverse age-related diseases. Its primary focus involves targeting senescent cells, designing senolytic medicines to clear these cells from the body while leaving normal cells unaffected. The company's pipeline includes UBX1325 for age-related eye diseases like diabetic macular edema.

Founded in 2017, Devoted Health is dedicated to enhancing the health and well-being of older Americans by offering integrated Medicare Advantage plans. They provide personalized care through a combination of local providers, virtual and in-home care, dedicated guides, and advanced technology.

Stride Health, Inc. is a health benefits platform that specializes in providing affordable health coverage options for independent workers and part-time employees in the United States. The company offers a range of services, including dental plans, doctor and prescription insurance plans, and various health coverage options tailored to meet the needs of its customers. Stride Health simplifies the enrollment process by guiding users through selecting the most cost-effective health plans, aiming to optimize their tax benefits and enhance their take-home pay. Founded in 2013 and based in San Francisco, California, the company was previously known as Covered, Inc. and rebranded to Stride Health, Inc. in March 2013. Stride Health also provides personal advisory services to assist clients in navigating the complexities of their health insurance options.

Unity Biotechnology is a biotechnology company dedicated to developing therapeutics that prevent, halt, or reverse age-related diseases. Its primary focus involves targeting senescent cells, designing senolytic medicines to clear these cells from the body while leaving normal cells unaffected. The company's pipeline includes UBX1325 for age-related eye diseases like diabetic macular edema.

Virta Health is a San Francisco–based health technology company that specializes in treating type 2 diabetes through an online, physician-supported program. The company combines nutritional biochemistry, data science, and digital tools to deliver on-demand care via a continuous remote care platform, providing physicians and health coaches who guide patients to reduce blood sugar and lose weight without medications or surgery. Founded in 2014, Virta offers a treatment approach aimed at reversing type 2 diabetes and improving related metabolic and cardiovascular health.

Founded in 2017, Devoted Health is dedicated to enhancing the health and well-being of older Americans by offering integrated Medicare Advantage plans. They provide personalized care through a combination of local providers, virtual and in-home care, dedicated guides, and advanced technology.

Unity Biotechnology is a biotechnology company dedicated to developing therapeutics that prevent, halt, or reverse age-related diseases. Its primary focus involves targeting senescent cells, designing senolytic medicines to clear these cells from the body while leaving normal cells unaffected. The company's pipeline includes UBX1325 for age-related eye diseases like diabetic macular edema.

Jiff, Inc. is a technology company that specializes in providing a HIPAA-compliant platform for the healthcare industry, enabling the creation of personalized and private communities of care. Founded in 2010 and headquartered in Mountain View, California, Jiff focuses on enhancing communication between healthcare professionals and patients through innovative tools. One of its notable products is JiffPad, an educational platform for iPads that transforms doctor-patient conversations and images into videos, facilitating easier sharing and understanding within the privacy of patients' homes. The company also offers solutions that engage employees by linking company benefits and incentives to healthy behaviors, leveraging familiar wearables and applications. Jiff has formed strategic alliances with firms such as Towers Watson & Co. and Mercer, furthering its mission to improve healthcare delivery and employee engagement. As of April 2017, Jiff operates as a subsidiary of Castlight Health, Inc.

Lyra Health operates a digital health platform that enhances mental health care for employees by connecting them with a curated network of therapists and coaches. Founded in 2015 and based in Burlingame, California, Lyra uses matching technology to pair individuals with suitable providers based on their needs and preferences. The platform offers live video therapy, coaching, and digital self-care tools, ensuring faster access to care and better outcomes compared to traditional plans. Lyra assesses treatment effectiveness using clinical measures like the PHQ-9 and GAD-7 for conditions such as anxiety and depression. This approach results in significantly more people receiving care and achieving improved mental health outcomes.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Included Health is a healthcare company that provides a blend of virtual care, navigation, and community-based healthcare services to enhance the member experience. It combines advanced technology and a compassionate approach to deliver personalized care guidance and advocacy, ensuring that individuals receive the right care at the right time. The company's offerings include access to both virtual and in-person services for a range of healthcare needs, including urgent and primary care, behavioral health, and specialty care. By focusing on a member-centric model, Included Health aims to raise the standard of healthcare for everyone, making it simpler and more effective for individuals to navigate their health journey.

Lyra Health operates a digital health platform that enhances mental health care for employees by connecting them with a curated network of therapists and coaches. Founded in 2015 and based in Burlingame, California, Lyra uses matching technology to pair individuals with suitable providers based on their needs and preferences. The platform offers live video therapy, coaching, and digital self-care tools, ensuring faster access to care and better outcomes compared to traditional plans. Lyra assesses treatment effectiveness using clinical measures like the PHQ-9 and GAD-7 for conditions such as anxiety and depression. This approach results in significantly more people receiving care and achieving improved mental health outcomes.

Jiff, Inc. is a technology company that specializes in providing a HIPAA-compliant platform for the healthcare industry, enabling the creation of personalized and private communities of care. Founded in 2010 and headquartered in Mountain View, California, Jiff focuses on enhancing communication between healthcare professionals and patients through innovative tools. One of its notable products is JiffPad, an educational platform for iPads that transforms doctor-patient conversations and images into videos, facilitating easier sharing and understanding within the privacy of patients' homes. The company also offers solutions that engage employees by linking company benefits and incentives to healthy behaviors, leveraging familiar wearables and applications. Jiff has formed strategic alliances with firms such as Towers Watson & Co. and Mercer, furthering its mission to improve healthcare delivery and employee engagement. As of April 2017, Jiff operates as a subsidiary of Castlight Health, Inc.

Stride Health, Inc. is a health benefits platform that specializes in providing affordable health coverage options for independent workers and part-time employees in the United States. The company offers a range of services, including dental plans, doctor and prescription insurance plans, and various health coverage options tailored to meet the needs of its customers. Stride Health simplifies the enrollment process by guiding users through selecting the most cost-effective health plans, aiming to optimize their tax benefits and enhance their take-home pay. Founded in 2013 and based in San Francisco, California, the company was previously known as Covered, Inc. and rebranded to Stride Health, Inc. in March 2013. Stride Health also provides personal advisory services to assist clients in navigating the complexities of their health insurance options.

Unity Biotechnology is a biotechnology company dedicated to developing therapeutics that prevent, halt, or reverse age-related diseases. Its primary focus involves targeting senescent cells, designing senolytic medicines to clear these cells from the body while leaving normal cells unaffected. The company's pipeline includes UBX1325 for age-related eye diseases like diabetic macular edema.

Jiff, Inc. is a technology company that specializes in providing a HIPAA-compliant platform for the healthcare industry, enabling the creation of personalized and private communities of care. Founded in 2010 and headquartered in Mountain View, California, Jiff focuses on enhancing communication between healthcare professionals and patients through innovative tools. One of its notable products is JiffPad, an educational platform for iPads that transforms doctor-patient conversations and images into videos, facilitating easier sharing and understanding within the privacy of patients' homes. The company also offers solutions that engage employees by linking company benefits and incentives to healthy behaviors, leveraging familiar wearables and applications. Jiff has formed strategic alliances with firms such as Towers Watson & Co. and Mercer, furthering its mission to improve healthcare delivery and employee engagement. As of April 2017, Jiff operates as a subsidiary of Castlight Health, Inc.

Mevion Medical Systems, Inc. is a company specializing in the development of proton therapy systems for cancer treatment. Founded in 2004 and headquartered in Littleton, Massachusetts, Mevion has established itself as a leader in the radiation therapy sector by creating innovative and effective solutions that enhance cancer care. The company, formerly known as Still River Systems, transitioned to its current name in 2011. Its flagship product, the MEVION S250 Proton Therapy System, aims to combine the advantages of traditional proton therapy with reduced size, cost, and complexity. This advancement enhances beam reliability and system uptime, making proton therapy more accessible and economically viable for cancer centers worldwide. Mevion operates internationally, with additional offices in the United Kingdom, China, and Japan, serving a global clientele.

Included Health is a healthcare company that provides a blend of virtual care, navigation, and community-based healthcare services to enhance the member experience. It combines advanced technology and a compassionate approach to deliver personalized care guidance and advocacy, ensuring that individuals receive the right care at the right time. The company's offerings include access to both virtual and in-person services for a range of healthcare needs, including urgent and primary care, behavioral health, and specialty care. By focusing on a member-centric model, Included Health aims to raise the standard of healthcare for everyone, making it simpler and more effective for individuals to navigate their health journey.

Mevion Medical Systems, Inc. is a company specializing in the development of proton therapy systems for cancer treatment. Founded in 2004 and headquartered in Littleton, Massachusetts, Mevion has established itself as a leader in the radiation therapy sector by creating innovative and effective solutions that enhance cancer care. The company, formerly known as Still River Systems, transitioned to its current name in 2011. Its flagship product, the MEVION S250 Proton Therapy System, aims to combine the advantages of traditional proton therapy with reduced size, cost, and complexity. This advancement enhances beam reliability and system uptime, making proton therapy more accessible and economically viable for cancer centers worldwide. Mevion operates internationally, with additional offices in the United Kingdom, China, and Japan, serving a global clientele.

Included Health is a healthcare company that provides a blend of virtual care, navigation, and community-based healthcare services to enhance the member experience. It combines advanced technology and a compassionate approach to deliver personalized care guidance and advocacy, ensuring that individuals receive the right care at the right time. The company's offerings include access to both virtual and in-person services for a range of healthcare needs, including urgent and primary care, behavioral health, and specialty care. By focusing on a member-centric model, Included Health aims to raise the standard of healthcare for everyone, making it simpler and more effective for individuals to navigate their health journey.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

ImpoPharma, Inc. is a research and development pharmaceutical company based in Concord, Canada, established in 1996. The company specializes in the development of nasal and pulmonary drug products, offering a diverse range of formulations, including dry powder inhalers, metered nasal sprays, injectable products, ophthalmic solutions, and oral medications. Additionally, ImpoPharma provides a variety of topical products such as creams, gels, and solutions. The company's services extend to formulation development for both generic and innovative products, analytical testing, production process development, and manufacturing of clinical batches. ImpoPharma also engages in extensive support for clinical trials and regulatory submissions, helping to ensure compliance with agencies such as the FDA and other international regulatory bodies. As of January 2020, it operates as a subsidiary of Rubicon Research Canada Limited.

Mevion Medical Systems, Inc. is a company specializing in the development of proton therapy systems for cancer treatment. Founded in 2004 and headquartered in Littleton, Massachusetts, Mevion has established itself as a leader in the radiation therapy sector by creating innovative and effective solutions that enhance cancer care. The company, formerly known as Still River Systems, transitioned to its current name in 2011. Its flagship product, the MEVION S250 Proton Therapy System, aims to combine the advantages of traditional proton therapy with reduced size, cost, and complexity. This advancement enhances beam reliability and system uptime, making proton therapy more accessible and economically viable for cancer centers worldwide. Mevion operates internationally, with additional offices in the United Kingdom, China, and Japan, serving a global clientele.

Ariosa Diagnostics specializes in non-invasive prenatal screening tests. Its Harmony Prenatal Test is widely used and offers accurate risk assessment for common fetal chromosome conditions, reducing the need for invasive procedures like amniocentesis.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.

WorldHeart is a public company based in Salt Lake City, Utah, with additional offices in Oakland, California, and Herkenbosch, The Netherlands. The company focuses on the development and manufacturing of implantable ventricular assist devices (VADs) and mechanical circulatory support systems designed for both adults and children. WorldHeart specializes in a minimally invasive, magnetically levitated miniature rotary blood pump that aims to overcome significant challenges associated with existing VADs, such as stroke, bleeding, device failures, and the invasiveness of implantation procedures.

Ariosa Diagnostics specializes in non-invasive prenatal screening tests. Its Harmony Prenatal Test is widely used and offers accurate risk assessment for common fetal chromosome conditions, reducing the need for invasive procedures like amniocentesis.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.

Ariosa Diagnostics specializes in non-invasive prenatal screening tests. Its Harmony Prenatal Test is widely used and offers accurate risk assessment for common fetal chromosome conditions, reducing the need for invasive procedures like amniocentesis.

Mevion Medical Systems, Inc. is a company specializing in the development of proton therapy systems for cancer treatment. Founded in 2004 and headquartered in Littleton, Massachusetts, Mevion has established itself as a leader in the radiation therapy sector by creating innovative and effective solutions that enhance cancer care. The company, formerly known as Still River Systems, transitioned to its current name in 2011. Its flagship product, the MEVION S250 Proton Therapy System, aims to combine the advantages of traditional proton therapy with reduced size, cost, and complexity. This advancement enhances beam reliability and system uptime, making proton therapy more accessible and economically viable for cancer centers worldwide. Mevion operates internationally, with additional offices in the United Kingdom, China, and Japan, serving a global clientele.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.

Mevion Medical Systems, Inc. is a company specializing in the development of proton therapy systems for cancer treatment. Founded in 2004 and headquartered in Littleton, Massachusetts, Mevion has established itself as a leader in the radiation therapy sector by creating innovative and effective solutions that enhance cancer care. The company, formerly known as Still River Systems, transitioned to its current name in 2011. Its flagship product, the MEVION S250 Proton Therapy System, aims to combine the advantages of traditional proton therapy with reduced size, cost, and complexity. This advancement enhances beam reliability and system uptime, making proton therapy more accessible and economically viable for cancer centers worldwide. Mevion operates internationally, with additional offices in the United Kingdom, China, and Japan, serving a global clientele.

Ironwood Pharmaceuticals is a specialty pharmaceutical company focused on gastroenterology therapies. Its lead product is linaclotide, marketed as LINZESS in the United States and CONSTELLA elsewhere, for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. The company is advancing other GI candidates, including MD-7246, an oral non-opioid pain reliever for abdominal GI pain, and IW 3718, a gastric-retentive bile acid sequestrant in Phase III for GERD. Ironwood pursues collaborations to expand linaclotide’s reach in North America, China, Hong Kong, Macau, and Japan, with agreements involving Allergan and AstraZeneca and a license with Astellas for Japan. It operates an independent subsidiary, Microbia, that develops bioprocesses for pharmaceuticals and related industries. Founded in 1998, Ironwood is headquartered in Massachusetts.

CodeRyte is a leading provider of computer-assisted coding and clinical data extraction solutions tailored for the healthcare industry. The company offers advanced software products, including CodeAssist, which automates the coding process by integrating with user operational information systems, and CodeComplete, an outsourced coding solution. Additionally, CodeRyte's DataScout tool analyzes physician narratives to extract clinically relevant information from both free-text and structured medical records. By streamlining coding processes and improving data extraction, CodeRyte enables healthcare providers to secure appropriate reimbursements, enhance compliance, and make informed treatment and business decisions. Its solutions are utilized by many prominent physician practices, billing companies, and academic medical centers across the nation, positioning CodeRyte as a vital component of their coding and data-mining operations.

Ironwood Pharmaceuticals is a specialty pharmaceutical company focused on gastroenterology therapies. Its lead product is linaclotide, marketed as LINZESS in the United States and CONSTELLA elsewhere, for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. The company is advancing other GI candidates, including MD-7246, an oral non-opioid pain reliever for abdominal GI pain, and IW 3718, a gastric-retentive bile acid sequestrant in Phase III for GERD. Ironwood pursues collaborations to expand linaclotide’s reach in North America, China, Hong Kong, Macau, and Japan, with agreements involving Allergan and AstraZeneca and a license with Astellas for Japan. It operates an independent subsidiary, Microbia, that develops bioprocesses for pharmaceuticals and related industries. Founded in 1998, Ironwood is headquartered in Massachusetts.

Anadys Pharmaceuticals is a biopharmaceutical company based in San Diego, California, focused on developing treatments for chronic hepatitis C viral infections. The company is primarily working on ANA598, a direct-acting antiviral agent designed to inhibit the hepatitis C virus. Additionally, Anadys is investigating ANA773, an oral small-molecule inducer of endogenous interferons that activates the Toll-like receptor 7 pathway. Founded in 1992, Anadys Pharmaceuticals operates as a subsidiary of Hoffmann-La Roche Inc.

Ironwood Pharmaceuticals is a specialty pharmaceutical company focused on gastroenterology therapies. Its lead product is linaclotide, marketed as LINZESS in the United States and CONSTELLA elsewhere, for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. The company is advancing other GI candidates, including MD-7246, an oral non-opioid pain reliever for abdominal GI pain, and IW 3718, a gastric-retentive bile acid sequestrant in Phase III for GERD. Ironwood pursues collaborations to expand linaclotide’s reach in North America, China, Hong Kong, Macau, and Japan, with agreements involving Allergan and AstraZeneca and a license with Astellas for Japan. It operates an independent subsidiary, Microbia, that develops bioprocesses for pharmaceuticals and related industries. Founded in 1998, Ironwood is headquartered in Massachusetts.

CodeRyte is a leading provider of computer-assisted coding and clinical data extraction solutions tailored for the healthcare industry. The company offers advanced software products, including CodeAssist, which automates the coding process by integrating with user operational information systems, and CodeComplete, an outsourced coding solution. Additionally, CodeRyte's DataScout tool analyzes physician narratives to extract clinically relevant information from both free-text and structured medical records. By streamlining coding processes and improving data extraction, CodeRyte enables healthcare providers to secure appropriate reimbursements, enhance compliance, and make informed treatment and business decisions. Its solutions are utilized by many prominent physician practices, billing companies, and academic medical centers across the nation, positioning CodeRyte as a vital component of their coding and data-mining operations.

Ironwood Pharmaceuticals is a specialty pharmaceutical company focused on gastroenterology therapies. Its lead product is linaclotide, marketed as LINZESS in the United States and CONSTELLA elsewhere, for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. The company is advancing other GI candidates, including MD-7246, an oral non-opioid pain reliever for abdominal GI pain, and IW 3718, a gastric-retentive bile acid sequestrant in Phase III for GERD. Ironwood pursues collaborations to expand linaclotide’s reach in North America, China, Hong Kong, Macau, and Japan, with agreements involving Allergan and AstraZeneca and a license with Astellas for Japan. It operates an independent subsidiary, Microbia, that develops bioprocesses for pharmaceuticals and related industries. Founded in 1998, Ironwood is headquartered in Massachusetts.

Ironwood Pharmaceuticals is a specialty pharmaceutical company focused on gastroenterology therapies. Its lead product is linaclotide, marketed as LINZESS in the United States and CONSTELLA elsewhere, for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. The company is advancing other GI candidates, including MD-7246, an oral non-opioid pain reliever for abdominal GI pain, and IW 3718, a gastric-retentive bile acid sequestrant in Phase III for GERD. Ironwood pursues collaborations to expand linaclotide’s reach in North America, China, Hong Kong, Macau, and Japan, with agreements involving Allergan and AstraZeneca and a license with Astellas for Japan. It operates an independent subsidiary, Microbia, that develops bioprocesses for pharmaceuticals and related industries. Founded in 1998, Ironwood is headquartered in Massachusetts.

Illumina develops and sells advanced genomic sequencing tools and workflows used in research, clinical laboratories, and industry. It provides high-throughput sequencing instruments, consumables, and services that enable whole genome sequencing in humans and other organisms, as well as lower-throughput applications for targeted analysis such as viral and cancer screening. The company's technology supports analysis of DNA, RNA, and protein to study genetic variation and function, facilitating disease research, drug development, and molecular diagnostics in clinical settings. It emphasizes scalable, flexible solutions and strong customer service, aiming to advance personalized medicine through rapid delivery of innovative sequencing and analysis capabilities. In addition to sequencing, Illumina offers microarrays that enable cost-effective screening for consumer and agricultural applications, contributing to a broad portfolio across life sciences.

Ironwood Pharmaceuticals is a specialty pharmaceutical company focused on gastroenterology therapies. Its lead product is linaclotide, marketed as LINZESS in the United States and CONSTELLA elsewhere, for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. The company is advancing other GI candidates, including MD-7246, an oral non-opioid pain reliever for abdominal GI pain, and IW 3718, a gastric-retentive bile acid sequestrant in Phase III for GERD. Ironwood pursues collaborations to expand linaclotide’s reach in North America, China, Hong Kong, Macau, and Japan, with agreements involving Allergan and AstraZeneca and a license with Astellas for Japan. It operates an independent subsidiary, Microbia, that develops bioprocesses for pharmaceuticals and related industries. Founded in 1998, Ironwood is headquartered in Massachusetts.

CardioThoracic Systems designs, develops, and manufactures surgical products and systems for minimally invasive cardiac surgery. The Company's current products are designed to enable the majority of cardiothoracic surgeons, using their existing skills coupled with company-sponsored training, to perform MICS on a beating heart. The OPCAB (Off Pump Coronary Artery Bypass) and MIDCAB (Minimally Invasive Direct Coronary Artery Bypass) procedures eliminate the need for a heart-lung machine, and recent studies indicate that the MICS procedures reduce the trauma, procedural costs and post-surgical complications associated with conventional coronary artery bypass graft (CABG) surgery while providing long-term procedural success rates comparable to CABG surgery. CardioThoracic Systems was founded in 1994 and is based in Cupertino, California. As of November 15, 1999, CardioThoracic Systems, Inc. was acquired by Guidant Corp.

Anadys Pharmaceuticals is a biopharmaceutical company based in San Diego, California, focused on developing treatments for chronic hepatitis C viral infections. The company is primarily working on ANA598, a direct-acting antiviral agent designed to inhibit the hepatitis C virus. Additionally, Anadys is investigating ANA773, an oral small-molecule inducer of endogenous interferons that activates the Toll-like receptor 7 pathway. Founded in 1992, Anadys Pharmaceuticals operates as a subsidiary of Hoffmann-La Roche Inc.

Vical develops biopharmaceuticals focused on preventing and treating chronic or life-threatening infectious diseases and dermatologic conditions. Rooted in DNA vaccine and non-viral gene therapy technology, the company has built a portfolio of independent and partnered development programs. The first animal health products are on the market, while human products are advancing. In addition to infectious disease therapies, the company pursues treatments for skin diseases such as hyperhidrosis, Cutaneous T-cell lymphoma, and psoriasis. Its pipeline includes Sofpironium Bromide and other candidates such as BBI-3000 and BBI-6000.